Otavio Berwanger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Otavio Berwanger has a total of 491 co-authors. Here are the top co-authors by number of shared publications:
- Henrique Andrade Rodrigues Fonseca
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
6 shared publications - Luiz Vicente Rizzo
Hospital Israelita Albert Einstein, São Paulo, Brazil
6 shared publications - Frederico Monfardini
Hospital Israelita Albert Einstein, São Paulo, Brazil
4 shared publications - Lucas Petri Damiani
Intensive Care Department, Hospital São Paulo, Escola Paulista de Medicina, Universidade Federal de São Paulo - São Paulo (SP), Brazil
4 shared publications - Alexandre Biasi Cavalcanti
Brazilian Research in Intensive Care Network (BRICNet) - São Paulo (SP), Brazil
3 shared publications - Andrei Carvalho Sposito
Department of Internal Medicine, School of Medical Sciences, State University of Campinas, Campinas, Brazil
3 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38
Statistical analysis plan for a stepped-wedge cluster randomized clinical trial for the evaluation of the clinical impact of different telemedicine practices in intensive care units – TELESCOPE 2 trial
Background The optimal model for delivering Tele-ICU is still to be determined. In the TELE-critical Care verSus usual Care on ICU Performance (TELESCOPE) trial, implementing medical-led daily multidisciplinary rounds did not show evidence of improved clinical outcomes. The TELESCOPE 2 trial was therefore designed to evaluate whether expanding this model to include a structured […] ABSTRACT Background The optimal model for delivering Tele-ICU is still to be determined. In the TELE-critical Care verSus usual Care on ICU Performance (TELESCOPE) trial, implementing medical-led daily multidisciplinary rounds did not show evidence of improved clinical outcomes. The TELESCOPE 2 trial was therefore designed to evaluate whether expanding this model to include a structured […]
- 8 October 2026
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38
Open AccessStatistical analysis plan for a stepped-wedge cluster randomized clinical trial for the evaluation of the clinical impact of different telemedicine practices in intensive care units – TELESCOPE 2 trial
Background The optimal model for delivering Tele-ICU is still to be determined. In the TELE-critical Care verSus usual Care on ICU Performance (TELESCOPE) trial, implementing medical-led daily multidisciplinary rounds did not show evidence of improved clinical outcomes. The TELESCOPE 2 trial was therefore designed to evaluate whether expanding this model to include a structured […] ABSTRACT Background The optimal model for delivering Tele-ICU is still to be determined. In the TELE-critical Care verSus usual Care on ICU Performance (TELESCOPE) trial, implementing medical-led daily multidisciplinary rounds did not show evidence of improved clinical outcomes. The TELESCOPE 2 trial was therefore designed to evaluate whether expanding this model to include a structured […]
- Open Access
- 5 October 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (10)
Intensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial
Background: In high cardiovascular risk populations without prior stroke, intensive blood pressure (BP) lowering confers greater reductions in cardiovascular events than standard targets. However, optimal BP targets in patients with ischaemic stroke (IS) or TIA remain uncertain. The primary objective of the OPTIMAL-STROKE trial is to assess whether an intensive systolic BP (SBP) target (SBP < 120 mmHg) reduces major cardiovascular events in patients with previous IS or TIA compared to a standard SBP target (SBP < 140 mmHg). Study design: OPTIMAL-STROKE is a multicentre, randomised, controlled, open-label clinical trial with blinded and independent assessment of clinical outcomes and intention-to-treat primary analysis. Patients with a history of IS or TIA and high BP (SBP of 130–180 mmHg), clinically stable for at least 48 h prior to trial inclusion, are centrally randomised with concealed allocation in a 1:1 ratio to either an intensive BP control strategy targeting a SBP < 120 mmHg or a standard control strategy targeting a SBP < 140 mmHg. A total of 495 primary outcome events, 4368 patients enrolled. Study endpoints: The primary outcome is the first occurrence of a composite outcome of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina or hospitalisation for heart failure). Summary: OPTIMAL-STROKE will be the first adequately powered trial of intensive BP control in the prevention of major cardiovascular events in patients with a history of IS or TIA. Trial registration: The trial is registered at ClinicalTrials.gov (NCT04036409).
- 5 October 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (10)
Open AccessIntensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial
Background: In high cardiovascular risk populations without prior stroke, intensive blood pressure (BP) lowering confers greater reductions in cardiovascular events than standard targets. However, optimal BP targets in patients with ischaemic stroke (IS) or TIA remain uncertain. The primary objective of the OPTIMAL-STROKE trial is to assess whether an intensive systolic BP (SBP) target (SBP < 120 mmHg) reduces major cardiovascular events in patients with previous IS or TIA compared to a standard SBP target (SBP < 140 mmHg). Study design: OPTIMAL-STROKE is a multicentre, randomised, controlled, open-label clinical trial with blinded and independent assessment of clinical outcomes and intention-to-treat primary analysis. Patients with a history of IS or TIA and high BP (SBP of 130–180 mmHg), clinically stable for at least 48 h prior to trial inclusion, are centrally randomised with concealed allocation in a 1:1 ratio to either an intensive BP control strategy targeting a SBP < 120 mmHg or a standard control strategy targeting a SBP < 140 mmHg. A total of 495 primary outcome events, 4368 patients enrolled. Study endpoints: The primary outcome is the first occurrence of a composite outcome of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina or hospitalisation for heart failure). Summary: OPTIMAL-STROKE will be the first adequately powered trial of intensive BP control in the prevention of major cardiovascular events in patients with a history of IS or TIA. Trial registration: The trial is registered at ClinicalTrials.gov (NCT04036409).
- Open Access
- 8 May 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (2) , 172-188
Clinical Characterization of Patients With 5q Spinal Muscular Atrophy Types 2 and 3 in Brazil: A Cross‐Sectional Observational Study
Spinal muscular atrophy (SMA), linked to chromosome 5q, is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. It is classified into subtypes based on age at onset and the highest motor milestone achieved. This cross‐sectional observational study aimed to describe the clinical profile of patients with types 2 and 3 SMA followed within the Brazilian Public Health System (SUS). Clinical data from patients with types 2 and 3 SMA followed at nine national reference centers (2020–2021) were analyzed. A total of 155 patients were included: 76 with type 2 and 79 with type 3 SMA. Disease duration was longer in type 3 patients. Time from symptom onset to genetic confirmation was also longer in this group. Functional impairment was observed in both subtypes. Type 2 patients had lower HFMSE scores overall, though higher scores were seen among those on disease‐modifying therapies. In type 3, earlier symptom onset and longer disease duration were associated with worse motor outcomes. HFMSE scores varied with treatment use and disease duration. Findings reveal the clinical heterogeneity of SMA and emphasize the impact of diagnostic delays and disease duration on function. Early diagnosis and ongoing multidisciplinary care are crucial.
- 8 May 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (2) , 172-188
Open AccessClinical Characterization of Patients With 5q Spinal Muscular Atrophy Types 2 and 3 in Brazil: A Cross‐Sectional Observational Study
Spinal muscular atrophy (SMA), linked to chromosome 5q, is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. It is classified into subtypes based on age at onset and the highest motor milestone achieved. This cross‐sectional observational study aimed to describe the clinical profile of patients with types 2 and 3 SMA followed within the Brazilian Public Health System (SUS). Clinical data from patients with types 2 and 3 SMA followed at nine national reference centers (2020–2021) were analyzed. A total of 155 patients were included: 76 with type 2 and 79 with type 3 SMA. Disease duration was longer in type 3 patients. Time from symptom onset to genetic confirmation was also longer in this group. Functional impairment was observed in both subtypes. Type 2 patients had lower HFMSE scores overall, though higher scores were seen among those on disease‐modifying therapies. In type 3, earlier symptom onset and longer disease duration were associated with worse motor outcomes. HFMSE scores varied with treatment use and disease duration. Findings reveal the clinical heterogeneity of SMA and emphasize the impact of diagnostic delays and disease duration on function. Early diagnosis and ongoing multidisciplinary care are crucial.
- Open Access
- 28 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2313
Electrocardiographic Left Ventricular Mass Trajectories and the Effects of Treatment in Patients at Different Stages of Hypertension
Background: The comparison of left ventricular mass (LVM) at different BP levels and the effects of antihypertensive drug treatment on LVM are unknown. Objective: To compare the LVM of individuals with prehypertension and Stage 1 hypertension and assess the effects of treatment on LVM at these stages of hypertension. Methods: We estimated LVM in the PREVER-Prevention trial using Sokolow–Lyon and Cornell voltage and voltage–duration products before and after randomization to 18 months of treatment with low doses of chlorthalidone and amiloride or placebo in adults with JNC 7 “prehypertension” (systolic BP [SBP] of 120–139 mm Hg and diastolic BP [DBP] of 80–89 mm Hg). Similarly, in the PREVER-Treatment trial, we assessed these indices before and after randomization to 18 months of treatment with the chlorthalidone/amiloride combination or losartan in adults with JNC 7 “stage 1” hypertension (140–159 mm Hg or DBP of 90–99 mm Hg). Results: At baseline, the participants in the stage I hypertension trial exhibited higher mean LVM indices than those in the prehypertension trial. In the PREVER-Prevention trial, those randomized to the chlorthalidone/amiloride combination experienced a significant reduction in Sokolow–Lyon LVM indices compared to placebo (p = 0.02). In the PREVER-Treatment trial, those randomized to the chlorthalidone/amiloride combination or losartan experienced a similar reduction in electrocardiographic LVM during the 18 months of treatment (p < 0.01). Conclusions: The institution of low-dose antihypertensive drug therapy in prehypertension and treatment of patients with stage 1 hypertension has the potential to interrupt the progress of hypertensive cardiomyopathy.
- 28 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2313
Open AccessElectrocardiographic Left Ventricular Mass Trajectories and the Effects of Treatment in Patients at Different Stages of Hypertension
Background: The comparison of left ventricular mass (LVM) at different BP levels and the effects of antihypertensive drug treatment on LVM are unknown. Objective: To compare the LVM of individuals with prehypertension and Stage 1 hypertension and assess the effects of treatment on LVM at these stages of hypertension. Methods: We estimated LVM in the PREVER-Prevention trial using Sokolow–Lyon and Cornell voltage and voltage–duration products before and after randomization to 18 months of treatment with low doses of chlorthalidone and amiloride or placebo in adults with JNC 7 “prehypertension” (systolic BP [SBP] of 120–139 mm Hg and diastolic BP [DBP] of 80–89 mm Hg). Similarly, in the PREVER-Treatment trial, we assessed these indices before and after randomization to 18 months of treatment with the chlorthalidone/amiloride combination or losartan in adults with JNC 7 “stage 1” hypertension (140–159 mm Hg or DBP of 90–99 mm Hg). Results: At baseline, the participants in the stage I hypertension trial exhibited higher mean LVM indices than those in the prehypertension trial. In the PREVER-Prevention trial, those randomized to the chlorthalidone/amiloride combination experienced a significant reduction in Sokolow–Lyon LVM indices compared to placebo (p = 0.02). In the PREVER-Treatment trial, those randomized to the chlorthalidone/amiloride combination or losartan experienced a similar reduction in electrocardiographic LVM during the 18 months of treatment (p < 0.01). Conclusions: The institution of low-dose antihypertensive drug therapy in prehypertension and treatment of patients with stage 1 hypertension has the potential to interrupt the progress of hypertensive cardiomyopathy.
- Open Access
- 13 November 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAE1133
Longitudinal data collection in pediatric and adult patients with 5q spinal muscular atrophy in Latin America: LATAM RegistrAME study - a clinical registry study protocol
Highlights ■ LATAM RegistrAME is the first clinical registry study of spinal muscular atrophy linked to 5q-SMA in Latin America (LATAM), including all ages. ■ This study will provide the first clinical evidence of access to medication for 5q-SMA treatment in LATAM. ■ It will describe the functional assessment and ventilatory support of 5q-SMA patients with diverse sociodemographic aspects. ABSTRACT Spinal muscular atrophy is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. The most common form of
- 13 November 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAE1133
Open AccessLongitudinal data collection in pediatric and adult patients with 5q spinal muscular atrophy in Latin America: LATAM RegistrAME study - a clinical registry study protocol
Highlights ■ LATAM RegistrAME is the first clinical registry study of spinal muscular atrophy linked to 5q-SMA in Latin America (LATAM), including all ages. ■ This study will provide the first clinical evidence of access to medication for 5q-SMA treatment in LATAM. ■ It will describe the functional assessment and ventilatory support of 5q-SMA patients with diverse sociodemographic aspects. ABSTRACT Spinal muscular atrophy is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. The most common form of
- Open Access
- 17 October 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0821
Laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial
Highlights Tofacitinib use did not result in meaningful changes in hematological parameters. Tofacitinib use did not lead to clinically meaningful changes in liver enzymes. ABSTRACT Objective: Tofacitinib, an oral Janus kinase inhibitor, has been tested against a placebo in 289 patients with COVID-19 pneumonia. We analyzed the data from the tofacitinib- and placebotreated patient cohorts to evaluate the laboratory profiles between baseline and day 7. Methods: We performed post hoc analyses on the following laboratory tests over time during the
- 17 October 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0821
Open AccessLaboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial
Highlights Tofacitinib use did not result in meaningful changes in hematological parameters. Tofacitinib use did not lead to clinically meaningful changes in liver enzymes. ABSTRACT Objective: Tofacitinib, an oral Janus kinase inhibitor, has been tested against a placebo in 289 patients with COVID-19 pneumonia. We analyzed the data from the tofacitinib- and placebotreated patient cohorts to evaluate the laboratory profiles between baseline and day 7. Methods: We performed post hoc analyses on the following laboratory tests over time during the
- Open Access
- 22 July 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0652
Mortality, hospitalizations, and persistence of symptoms in the outpatient setting of the first COVID-19 wave in Brazil: results of SARS-Brazil cohort study
Highlights Previous influenza vaccination was associated with a reduced need for hospitalization after COVID-19 diagnosis. In 60 days of outpatient setting, four deaths occurred (three in the hospitalized and one in the non-hospitalized group). The persistence of more than two symptoms in 60 days was observed in 31.9% of patients. ABSTRACT Objective: To evaluate deaths, hospitalizations, and persistence of symptoms in patients with COVID-19 after infection in an outpatient setting during the first COVID-19 wave in Brazil. Methods: This prospective
- 22 July 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0652
Open AccessMortality, hospitalizations, and persistence of symptoms in the outpatient setting of the first COVID-19 wave in Brazil: results of SARS-Brazil cohort study
Highlights Previous influenza vaccination was associated with a reduced need for hospitalization after COVID-19 diagnosis. In 60 days of outpatient setting, four deaths occurred (three in the hospitalized and one in the non-hospitalized group). The persistence of more than two symptoms in 60 days was observed in 31.9% of patients. ABSTRACT Objective: To evaluate deaths, hospitalizations, and persistence of symptoms in patients with COVID-19 after infection in an outpatient setting during the first COVID-19 wave in Brazil. Methods: This prospective
- 2 July 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (1) , 82-85
Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial
- 2 July 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (1) , 82-85
Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial
- 27 December 2023
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 455, 121701
Characterization of the profile of patients with spinal muscular atrophy types 2 and 3 being followed up in the Brazilian public health system
- 27 December 2023
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 455, 121701
Characterization of the profile of patients with spinal muscular atrophy types 2 and 3 being followed up in the Brazilian public health system